ישראל - עברית - Ministry of Health

megapharm ltd - potassium sodium hydrogen citrate 2.427 g / 2.5 g - granules - potassium citrate - to dissolve uric acid stones in the urinary tract. prevention of further stone formation.

ישראל - עברית - Ministry of Health

padagis israel agencies ltd, israel - ascorbic acid; macrogols; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate anhydrous - אבקה להכנת תמיסה - potassium chloride 1.015 g; sodium ascorbate 5.9 g; macrogols 100 g; sodium chloride 2.691 g; sodium sulfate anhydrous 7.5 g; ascorbic acid 4.7 g - electrolytes in combination with other drugs - electrolytes in combination with other drugs - for bowel cleansing prior to any clinical procedures requiring a clean bowel e.g. bowel endoscopy or radiology.

ישראל - עברית - Ministry of Health

sam-on ltd - potassium citrate; sodium citrate - טבליה - potassium citrate 330 mg; sodium citrate 300 mg - other urologicals - urinary alkalizer.

ישראל - עברית - Ministry of Health

teva medical ltd - dextrose monohydrate; potassium chloride; sodium chloride - תמיסה להזרקה - sodium chloride 330 mg / 100 ml; potassium chloride 150 mg / 100 ml; dextrose monohydrate 5 g / 100 ml - potassium chloride - electrolyte solutions - indicated for replenishing water, certain electrolytes and calories required by the clinical condition of the patient.

ישראל - עברית - Ministry of Health

steba laboratories ltd., israel - padeliporfin dipotassium - אבקה להכנת תמיסה לאינפוזיה - padeliporfin dipotassium 200 mg

ישראל - עברית - Ministry of Health

steba laboratories ltd., israel - padeliporfin dipotassium - אבקה להכנת תמיסה לאינפוזיה - padeliporfin dipotassium 400 mg

ישראל - עברית - Ministry of Health

taro pharmaceutical industries ltd - macrogols; potassium chloride; sodium bicarbonate; sodium chloride - אבקה להכנת תמיסה - macrogols 315.0 g; potassium chloride 1.1175 g; sodium bicarbonate 4.2840 g; sodium chloride 8.4240 g - mineral salts in combination - mineral salts in combination - bowel cleansing prior to colonoscopy and barium enema x-ray examinations.

ישראל - עברית - Ministry of Health

organon pharma israel ltd., israel - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: ocsaar is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to ocsaar is not recommended. renal protection in type-2 diabetic patients with proteinuria: ocsaar is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. ocsaar is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of ocsaar on the primary deposite endpoint was lar

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - losartan potassium - טבליה - losartan potassium 12.5 mg - losartan - losartan - hypertension: losardex is indicated for the treatment of hypertension. heart failure: losardex is indicated for the treatment of heart failure (nyha ii) , when treatment with an ace inhibitor is no longer considered appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended.

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: losardex is indicated for the treatment of hypertension. heart failure: losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended. renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventric